Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea.
BACKGROUND:This study aimed to describe patterns of long-term antithrombotic use in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) in Korea and their impacts on clinical events before introduction of non-vitamin K antagonist oral anticoagulants (NOAC) into practice...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6214500?pdf=render |
| _version_ | 1818564040012595200 |
|---|---|
| author | Hee-Joon Bae Ji Hoe Heo Keun-Hwa Jung Yong-Seok Lee Keun-Sik Hong Woo-Keun Seo Jaseong Koo Jae-Kwan Cha Mi Ji Lee Bo-Jeong Seo Young-Joo Kim Seongsik Kang Jinmi Seok Juneyoung Lee Chin-Sang Chung |
| author_facet | Hee-Joon Bae Ji Hoe Heo Keun-Hwa Jung Yong-Seok Lee Keun-Sik Hong Woo-Keun Seo Jaseong Koo Jae-Kwan Cha Mi Ji Lee Bo-Jeong Seo Young-Joo Kim Seongsik Kang Jinmi Seok Juneyoung Lee Chin-Sang Chung |
| author_sort | Hee-Joon Bae |
| collection | DOAJ |
| description | BACKGROUND:This study aimed to describe patterns of long-term antithrombotic use in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) in Korea and their impacts on clinical events before introduction of non-vitamin K antagonist oral anticoagulants (NOAC) into practice in 2015. METHODS:Patients with NVAF who were admitted due to the AIS and discharged no later than 2008 were enrolled retrospectively. Data were collected at 11 time points during the first 3 years of follow-up. The primary outcome event was a composite of stroke recurrence, major bleeding, and death. Vitamin K antagonist (VKA) users were categorized into a well-controlled INR group and a poorly-controlled INR group (modified TTR ≥47.0% vs <47.0%). RESULTS:Of 1,350 patients enrolled in this study, 95% were on antithrombotic medications at discharge. The rate of VKA usage decreased over time (77% and 40% at discharge and 3 years, respectively). The cumulative event rates of the primary outcome differed by treatment patterns. Among the 10 most frequent treatment types, the highest outcome rate was observed in patients who started with VKA-only therapy but discontinued VKAs during follow-up without restarting (70.2%); this was followed by those starting with antiplatelet-only therapy and stopping it without restart (66.7%). Among VKA users, the 3-year cumulative primary outcome rates were higher in the poorly-controlled INR group than the well-controlled INR group (24.5% vs 15.7%; p = 0.015). CONCLUSION:Our study revealed that, in pre-NOAC era, there was a wide spectrum of long-term antithrombotic use. The incidence of the composite outcome also varied by patterns of antithrombotic use. |
| first_indexed | 2024-12-14T01:24:11Z |
| format | Article |
| id | doaj.art-7a7390354a1c49c19754faf0febef5d0 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T01:24:11Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7a7390354a1c49c19754faf0febef5d02022-12-21T23:22:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011311e020280310.1371/journal.pone.0202803Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea.Hee-Joon BaeJi Hoe HeoKeun-Hwa JungYong-Seok LeeKeun-Sik HongWoo-Keun SeoJaseong KooJae-Kwan ChaMi Ji LeeBo-Jeong SeoYoung-Joo KimSeongsik KangJinmi SeokJuneyoung LeeChin-Sang ChungBACKGROUND:This study aimed to describe patterns of long-term antithrombotic use in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) in Korea and their impacts on clinical events before introduction of non-vitamin K antagonist oral anticoagulants (NOAC) into practice in 2015. METHODS:Patients with NVAF who were admitted due to the AIS and discharged no later than 2008 were enrolled retrospectively. Data were collected at 11 time points during the first 3 years of follow-up. The primary outcome event was a composite of stroke recurrence, major bleeding, and death. Vitamin K antagonist (VKA) users were categorized into a well-controlled INR group and a poorly-controlled INR group (modified TTR ≥47.0% vs <47.0%). RESULTS:Of 1,350 patients enrolled in this study, 95% were on antithrombotic medications at discharge. The rate of VKA usage decreased over time (77% and 40% at discharge and 3 years, respectively). The cumulative event rates of the primary outcome differed by treatment patterns. Among the 10 most frequent treatment types, the highest outcome rate was observed in patients who started with VKA-only therapy but discontinued VKAs during follow-up without restarting (70.2%); this was followed by those starting with antiplatelet-only therapy and stopping it without restart (66.7%). Among VKA users, the 3-year cumulative primary outcome rates were higher in the poorly-controlled INR group than the well-controlled INR group (24.5% vs 15.7%; p = 0.015). CONCLUSION:Our study revealed that, in pre-NOAC era, there was a wide spectrum of long-term antithrombotic use. The incidence of the composite outcome also varied by patterns of antithrombotic use.http://europepmc.org/articles/PMC6214500?pdf=render |
| spellingShingle | Hee-Joon Bae Ji Hoe Heo Keun-Hwa Jung Yong-Seok Lee Keun-Sik Hong Woo-Keun Seo Jaseong Koo Jae-Kwan Cha Mi Ji Lee Bo-Jeong Seo Young-Joo Kim Seongsik Kang Jinmi Seok Juneyoung Lee Chin-Sang Chung Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. PLoS ONE |
| title | Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. |
| title_full | Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. |
| title_fullStr | Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. |
| title_full_unstemmed | Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. |
| title_short | Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. |
| title_sort | antithrombotic treatments in patients with acute ischemic stroke and non valvular atrial fibrillation before introduction of non vitamin k antagonist oral anticoagulants into practice in korea |
| url | http://europepmc.org/articles/PMC6214500?pdf=render |
| work_keys_str_mv | AT heejoonbae antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT jihoeheo antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT keunhwajung antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT yongseoklee antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT keunsikhong antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT wookeunseo antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT jaseongkoo antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT jaekwancha antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT mijilee antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT bojeongseo antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT youngjookim antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT seongsikkang antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT jinmiseok antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT juneyounglee antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea AT chinsangchung antithrombotictreatmentsinpatientswithacuteischemicstrokeandnonvalvularatrialfibrillationbeforeintroductionofnonvitaminkantagonistoralanticoagulantsintopracticeinkorea |